ClinicalTrials.gg
CompletedNCT02224690GWPCARE4Updated Sep 28, 2022Results posted

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

A Phase 3 interventional study of GWP42003-P 20 mg/kg/day Dose and Placebo in Epilepsy and Lennox-Gastaut Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 24 sites in 3 countries. Open to participants aged 2 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionLennox Gastaut SyndromeRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lennox Gastaut Syndrome
Why
  1. The study's listed conditions name Lennox Gastaut Syndrome, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
2 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing cannabidiol in Lennox Gastaut Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Cannabidiol · Lennox Gastaut Syndrome.

Enrollment
3rd of 13
171 · median 40
Started
2015
with 2 others
Phase 3
7 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
6 of 13
Jazz Pharmaceuticals

Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 1st registered.

Lennox Gastaut Syndrome

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

Browse Lennox Gastaut Syndrome studies →

Open to participants now

2 of the 13 studies testing cannabidiol in Lennox Gastaut Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 2 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing cannabidiol in Lennox Gastaut Syndrome, or all of them as a file.
02

Study summary

To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).

Read the detailed description

This study was a 1:1 randomized, double-blind, 14-week comparison of 20 milligram [mg] per kilogram [kg] per day [mg/kg/day] of GWP42003-P versus placebo. The treatment period consisted of a 2-week titration period followed by a 12-week maintenance period. The study determined the efficacy, safety and tolerability of GWP42003-P compared with placebo. The dose was recommended by the Data Safety Monitoring Committee (DSMC) after assessment of safety and pharmacokinetic data from Part A of study GWEP1332. The first participants enrolled into this study after the DSMC reviewed the safety data from Part A of study GWEP1332. Following study completion, all participants were invited to continue to receive GWP42003-P in an open label extension (OLE) study (under a separate protocol).

03

Conditions studied

  • Epilepsy
  • Lennox-Gastaut Syndrome

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

In context

Lennox Gastaut Syndrome Reclassified

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

This study's enrollment of 171 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.

Browse Lennox Gastaut Syndrome studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Compared within Lennox Gastaut Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must have been male or female aged between 2 and 55 years (inclusive).
  • Participant must have had a documented history of Lennox-Gastaut syndrome. This included written documentation of having met electroencephalogram (EEG) diagnostic criteria during the participant's history and evidence of at least 1 type of generalized seizure, including drop seizures (atonic, tonic, tonic-clonic or myoclonic) for at least 6 months.
  • Participants had a history of slow (\<3.0 Hertz) spike-and-wave pattern in an EEG prior to the enrollment into the baseline period.
  • Participants were ; that is having documented failures on more than one antiepileptic drug (AED).
  • Participant must have been taking 1 or more AEDs at a dose which has been stable for at least 4 weeks prior to screening.
  • All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation [VNS]) must have been stable for 4 weeks prior to screening and participant is willing to maintain a stable regimen throughout the study. The ketogenic diet and VNS treatments are not accounted as an AED.

Key Exclusion Criteria:

  • Etiology of participant's seizures was a progressive neurologic disease. Participants with tuberous sclerosis were not excluded from study participation, unless there was a progressive tumor.
  • Participant had an anoxic episode requiring resuscitation within 6 months of screening.
  • Participant had unstable medical conditions other than epilepsy.
  • Participant had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or randomization, other than epilepsy.
  • Participant was currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex®) within the 3 months prior to study entry and was unwilling to abstain for the duration of the study.
  • Participant had any known or suspected to cannabinoids or any of the of the Medicinal Product (IMP), such as sesame oil.
  • Participant had been part of a clinical trial involving another IMP in the previous 6 months.
  • Participant had significantly impaired hepatic function at screening or randomization ( [ALT] >5 x [ULN] or total [TBL] >2 x ULN) OR the ALT or Aspartate aminotransferase (AST) >3 x ULN and (TBL >2 x ULN or >1.5). This criterion can only be confirmed once the laboratory results are available; Participants randomized into the study who are later found not to meet this criterion should be withdrawn from the study.
  • Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last month or at screening.
  • Participant was taking more than 4 concurrent AEDs.
  • Participant was taking corticotropins in the 6 months prior to screening.
  • Participant was taking long-term systemic (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception was made of prophylactic medication, for example, idiopathic nephrotic syndrome or asthma.
  • Participant was taking felbamate, and they had been taking it for less than 1 year prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    GWP42003-P 20 mg/kg/day Dose

    Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P 20 mg/kg/day Dose

  • Placebo comparator
    Placebo

    Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.

    Drug: Placebo

Interventions

  • DrugGWP42003-P 20 mg/kg/day Dose

    Drug page: Cannabidiol

    GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

    Also known as: Cannabidiol, Epidiolex

  • DrugPlacebo

    Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

07

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period

    Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (frequency during the treatment period - frequency during baseline/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \*28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

    Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)

Secondary outcomes

  1. Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period

    Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.

    Time frame: Baseline to EOT (Day 99) or ET

  2. Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period

    Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.

    Time frame: Baseline to EOT (Day 99) or ET

  3. Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)

    The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

    Time frame: Baseline to Last Visit (Day 99) or ET

08

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneGWP42003-P 20 mg/kg/Day DosePlacebo
Started8685
Safety analysis set8685
Intent to treat (itt) analysis set8685
Completed7284
Not completed141
Withdrew: Adverse event81
Withdrew: Met withdrawal criteria40
Withdrew: Use of g-tube10
Withdrew: Did not meet eligibility criteria10

Outcome measures

PrimaryPercentage Change From Baseline In Drop Seizure Frequency During The Treatment Period

Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (frequency during the treatment period - frequency during baseline/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \*28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

Time frame:
Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Reported as:
Median · percentage change
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
percentage changeGWP42003-P 20 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period-43.90 (-69.62 to 1.93)-21.80 (-45.72 to 1.74)
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0135 · Median difference (final values): -17.21 · 95% CI -30.32 to -4.09Calculated using the Hodges-Lehmann approach
SecondaryNumber Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period

Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period3820
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0043 · Odds ratio (or): 2.57 · 95% CI 1.33 to 4.97Calculated using a Cochran-Mantel-Haenszel test stratified by age group (2-5, 6-11, 12-17 and 18-55 years)
SecondaryPercentage Change From Baseline In Total Seizure Frequency During The Treatment Period

Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Median · percentage change
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
percentage changeGWP42003-P 20 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period-41.24 (-62.85 to -13.00)-13.70 (-45.00 to 7.27)
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0005 · Mean difference (final values): -21.13 · 95% CI -33.26 to -9.37Calculated using the Hodges-Lehmann approach
SecondarySubject/Caregiver Global Impression Of Change Assessment (S/CGIC)

The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Count of participants · Participants
Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)
ParticipantsGWP42003-P 20 mg/kg/Day DosePlacebo
Very Much Improved155
Much Improved149
Slightly Improved2015
No Change2743
Slightly Worse79
Much Worse12
Very Much Worse02
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Regression, Logistic · p = 0.0012 · Odds ratio (or): 2.54 · 95% CI 1.45 to 4.47Odds of participants recording a lower score (improvement) on a continuous scale

Adverse events

Collected over Day 1 through Day 137 (Safety Follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 20 mg/kg/Day Dose—20/86 (23.3%)53/86 (61.6%)
Placebo—4/85 (4.7%)43/85 (50.6%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventGWP42003-P 20 mg/kg/Day DosePlacebo
Alanine aminotransferase increasedInvestigations4/860/85
Aspartate aminotransferase increasedInvestigations4/860/85
PneumoniaInfections and infestations3/860/85
Gamma-glutamyltransferase increasedInvestigations3/860/85
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/860/85
DehydrationMetabolism and nutrition disorders0/862/85
Viral infectionInfections and infestations2/860/85
ConvulsionNervous system disorders2/860/85
HypoxiaRespiratory, thoracic and mediastinal disorders2/860/85
PyrexiaGeneral disorders0/861/85
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGWP42003-P 20 mg/kg/Day DosePlacebo
DiarrhoeaGastrointestinal disorders16/867/85
VomitingGastrointestinal disorders8/8614/85
SomnolenceNervous system disorders12/868/85
PyrexiaGeneral disorders11/867/85
Decreased appetiteMetabolism and nutrition disorders11/862/85
SedationNervous system disorders7/861/85
Nasal congestionRespiratory, thoracic and mediastinal disorders7/862/85
Upper respiratory tract infectionInfections and infestations2/866/85
RashSkin and subcutaneous tissue disorders6/861/85
ConvulsionNervous system disorders3/865/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)GWP42003-P 20 mg/kg/Day DosePlaceboTotal
Mean15.478 ± 8.68515.284 ± 9.794515.381 ± 9.2264
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 20 mg/kg/Day DosePlaceboTotal
Female414283
Male454388
09

Study locations

24 sites
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia 30328, United States
  • Chicago, Illinois 60611, United States
  • Ames, Iowa 50010, United States
  • Iowa City, Iowa 52242, United States
  • Lexington, Kentucky 40536, United States
  • Boston, Massachusetts 02114, United States
  • Saint Paul, Minnesota 55102, United States
  • St Louis, Missouri 63131, United States
  • Lebanon, New Hampshire 03756, United States
  • Rochester, New York 14642, United States
  • The Bronx, New York 10467, United States
  • Philadelphia, Pennsylvania 19104-4399, United States
  • Dallas, Texas 75251, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 81143, United States
  • Winchester, Virginia 22601, United States
  • Denekamp, BV Zwolle 8025, Netherlands
  • Bydgoszcz, 85-080, Poland
  • Gdansk, 80-952, Poland
  • Krakow, 30-349, Poland
  • Lublin, 20-093, Poland
  • Lublin, 20-718, Poland
  • Poznan, 60-355, Poland
10

References and documents

Publications

  • Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. PubMed 29395273 ↗
  • Specchio N, Auvin S, Greco T, Lagae L, Nortvedt C, Zuberi SM. Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials. CNS Drugs. 2025 Oct;39(10):1025-1036. doi: 10.1007/s40263-025-01201-8. Epub 2025 Aug 7. PubMed 40775196 ↗
  • Auvin S, Nortvedt C, Fuller DS, Sahebkar F. Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials. Epilepsia. 2023 Jul;64(7):1812-1820. doi: 10.1111/epi.17618. Epub 2023 Apr 28. PubMed 37052803 ↗
  • Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4. PubMed 33825230 ↗
  • Privitera M, Bhathal H, Wong M, Cross JH, Wirrell E, Marsh ED, Mazurkiewicz-Beldzinska M, Villanueva V, Checketts D, Knappertz V, VanLandingham K. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. Epilepsia. 2021 May;62(5):1130-1140. doi: 10.1111/epi.16878. Epub 2021 Apr 2. PubMed 33797076 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Mar 2016, 10 months.

Results were first posted in Jul 2018, 2 years 4 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Aug 25, 2014
StartActual
Apr 28, 2015
Primary completionActual
Mar 18, 2016
CompletionActual
Mar 18, 2016
Results delay requested
Feb 22, 2017
Results first posted
Jul 27, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02224690
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Apr 28, 2015
Primary completion
Mar 18, 2016
Completion
Mar 18, 2016
Results posted
Jul 27, 2018
Last update
Sep 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion